Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Desmoid tumors have an extremely variable natural history. The uncertainty behind desmoid behavior reflects the complexity, which subtends its development and non-linear advancement. Apart from Wnt- βcatenin mutation, estrogen receptors, and COX-2 overexpression, little is known about the ability of desmoids to grow and recur while being unable to metastasize. Several tumors have been shown to express the CXCR4/CXCR7/CXCL12 axis, whose functions are essential for tumoral development.
Aims: This study aimed to investigate the expression of the CXCR4/CXCR7/CXCL12 axis in primary desmoid tumors and discuss the potential role of this key-signaling as an antiangiogenic therapeutic strategy.
Methods: In this study, 3 μm-thick consecutive sections from each formalin-fixed and paraffin-embedded tissue block were treated with mouse monoclonal antibodies developed against CD34, CXCR4, CXCR7, and CXCL12.
Results: Two distinct vessel populations: CXCR4 and CXCR4- vessels, have been found. Similarly, chemokine receptor CXCR7 expression in the entire desmoid tumor series positively stained a portion of tumor-associated vessels, identifying two distinct subpopulations of vessels: CXCR7 and CXCR7- vessels. All 8 neoplastic tissue samples expressed CXCL12. Immunohistochemical positivity was identified in both stromal and endothelial vascular cells. Compared to CXCR4 and CXCR7, the vast majority of tumor-associated vessels were found to express this chemokine.
Conclusion: It is the first time, as per our knowledge, that CXCR4/CXCR7/CXCL12 axis expression has been identified in a desmoid type-fibromatosis series. CXCL12 expression by neoplastic cells, together with CXCR4 and CXCR7 expression by a subgroup of tumor-associated vessels, was detected in all desmoid tumor tissue samples examined. Since chemokines are known contributors to neovascularization, CXCR4/CXCR7/CXCL12 axis may play a role in angiogenesis in this soft-tissue tumor histotype, thereby supporting its growth.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871520623666230207091429 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates.
Exp Hematol Oncol
November 2023
Department of Urology, Urological Research Laboratory, Translational UroOncology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany.
Article Synopsis
- The study looks at how a special chemical (CXCL12) interacts with proteins (CXCR4 and CXCR7) that help tumors grow and spread, especially in germ cell tumors (GCT) like seminoma and yolk-sac tumors.
- Researchers tested a new treatment called CXCR4-NDC, which targets the CXCR4 protein, and found it could kill cancer cells without harming normal cells.
- The findings suggest that this treatment could help fight GCT by stopping tumor cells from growing and moving, and it also revealed how these proteins work together in cancer.
Exploring the CXCR4/CXCR7/CXCL12 Axis in Primary Desmoid Tumors.
Anticancer Agents Med Chem
December 2023
Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Rozzano, Milan, 20089, Italy.
Background: Desmoid tumors have an extremely variable natural history. The uncertainty behind desmoid behavior reflects the complexity, which subtends its development and non-linear advancement. Apart from Wnt- βcatenin mutation, estrogen receptors, and COX-2 overexpression, little is known about the ability of desmoids to grow and recur while being unable to metastasize.
View Article and Find Full Text PDFRelevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
Pharmacol Res
November 2020
Idorsia Pharmaceuticals Ltd, Department of Clinical Pharmacology, Hegenheimermattweg 91, 4123 Allschwil, Switzerland. Electronic address:
Article Synopsis
- * Alterations in the CXCR4/CXCR7-CXCL12 axis are linked to several diseases, including cancer and autoimmune conditions, which suggests its importance in disease progression and treatment.
- * Despite promising clinical modulators for CXCR4 and CXCL12 already in development, research on CXCR7 modulators is limited, indicating a need for further studies in this area.
CXCR4/CXCR7/CXCL12-Axis in Follicular Thyroid Carcinoma.
J Cancer
February 2018
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Follicular thyroid carcinoma's (FTC) often benign course is partially due to adjuvant radioactive iodine (RAI) treatment. However, once the tumour has spread and fails to retain RAI, the therapeutic options are limited and the outcome is poor. In this subset of patients, the identification of novel druggable biomarkers appears invaluable.
View Article and Find Full Text PDFCXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma.
Br J Cancer
December 2017
Department of Surgery (A), Heinrich-Heine-University and University Hospital Duesseldorf, Moorenstr. 5, Duesseldorf 40225, Germany.
Background: Medullary thyroid carcinoma (MTC) is a rare and challenging endocrine malignancy. Once spread, the therapeutic options are limited and the outcome poor. For these patients, the identification of new druggable biological markers is of great importance.
View Article and Find Full Text PDF